Wen Ken Group is a long-established pharmaceutical company based in Singapore, with a strong foothold in the market since its foundation in 1937. The company's commitment to providing affordable healthcare aligns with its slogan, "Providing affordable healthcare for the benefit of all." Wen Ken Group focuses on the production of traditional Chinese medicine (TCM), over-the-counter (OTC) medications, and health supplements, emphasizing continuous research and development to enhance its products and better serve the community. The company boasts a dedicated R&D team led by Professor Zhu Wen Jun and Mr. Young Siew Wah, each with over 30 years of experience in TCM research and development. This expertise, coupled with modern facilities and advanced lab equipment, enables Wen Ken Group to ensure the safety, quality, and efficacy of its pharmaceutical products. Furthermore, the company offers holistic contract manufacturing services (OEM) for businesses aiming to develop high-quality products with various dosage forms. Wen Ken Group has established itself as a market leader in the TCM industry, not only in Singapore and Malaysia but also in other international markets. While the details of the last investment and investors are not available, the company's ongoing focus on medical advancement and commitment to serving the community positions it as an attractive prospect for venture capital looking to invest in the pharmaceutical sector.
There is no investment information
No recent news or press coverage available for Wen Ken Group.